CAR-T Therapy and CRISPR/Cas9 in Cancer Treatment

CAR-T and CRISPR/Cas9 are two biotechnologies that have exhibited promising results in the field of cancer treatment. They are also constantly remarked for their consistent progress in clinical and preclinical trials alike. CAR-T Therapy is a type of immunotherapy and it redirects T cells to target cancer cells. Additionally, CRISPR/Cas9 Gene Editing is a gene editing tool that enhances the capabilities of CAR-T Therapy. Individually, they have shown proficient abilities in defense against cancer. However, they have both experienced limitations in its ability to tackle many types of cancers beyond blood cancers. Particularly, they are in need of progress towards their effect against solid malignancies. Although they seem to be a reliable option for cancer treatment even on their own, they seem to fall short when it comes to a multitude of different cancers. However, together they can form a powerful treatment against other types of cancers beyond blood cancers including solid malignancies.